Vitaxin Explained

Vitaxin (MEDI-523) is a humanized monoclonal antibody against the vascular integrin alpha-v beta-3.[1] It is shown to be a promising angiogenesis inhibitor used in the treatment of some forms of cancer. Vitaxin was in 2002 being studied for rheumatoid arthritis.[2] It is the developmental precursor of Etaracizumab (MEDI-522). Both are derived from the mouse antibody LM609.[3]

Vitaxin is safe for humans. It has little effect on advanced cancer.[3]

Notes and References

  1. Cherrington JM, Strawn LM, Shawver LK . New paradigms for the treatment of cancer: the role of anti-angiogenesis agents . Vande Woude GF, Klein G . Advances in Cancer Research . Academic Press . 79 . 1–38 (27) . 2000 . 10818676 . 10.1016/s0065-230x(00)79001-4 . 978-0-12-006679-7 .
  2. Wilder RL . Integrin alpha V beta 3 as a target for treatment of rheumatoid arthritis and related rheumatic diseases . Annals of the Rheumatic Diseases . 61 . Suppl 2 . ii96–ii99 . November 2002 . 12379637 . 1766704 . 10.1136/ard.61.suppl_2.ii96 .
  3. McNeel DG, Eickhoff J, Lee FT, King DM, Alberti D, Thomas JP, Friedl A, Kolesar J, Marnocha R, Volkman J, Zhang J, Hammershaimb L, Zwiebel JA, Wilding G . 6 . Phase I trial of a monoclonal antibody specific for alphavbeta3 integrin (MEDI-522) in patients with advanced malignancies, including an assessment of effect on tumor perfusion . Clinical Cancer Research . 11 . 21 . 7851–7860 . November 2005 . 16278408 . 10.1158/1078-0432.CCR-05-0262 . 33227412 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Vitaxin".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.